ChenoCentryx (CCXI) Files $69M IPO
Tweet
Share
E-mail
ChenoCentryx, Inc. (Nasdaq: CCXI), filed a registration with the U.S. Securities and Exchange Commission for an Initial Public Offering of its Common Stock. The proposed maximum offering price is $69 million. ChenoCentryx plans to list on the Nasdaq Global Market under the ticker "CCXI."
The offering is being made through J.P. Morgan, Citi, and Cowen and Company.
ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer.
The offering is being made through J.P. Morgan, Citi, and Cowen and Company.
ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer.
Are you missing key trading opportunities? Upgrade to StreetInsider Premium and get a step ahead of the market - FREE TRIAL!
Create E-mail Alert Related Categories
IPOsRelated Entities
JPMorgan, Citi, Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
